Use of Peptide Microarrays for Fast and Informative Profiling of Therapeutic Antibody Formulation Conditions

Methods to optimize the solution behavior of therapeutic proteins are frequently time-consuming, provide limited information, and often use milligram quantities of material. Here, we present a simple, versatile method that provides valuable information to guide the identification and comparison of f...

Full description

Saved in:
Bibliographic Details
Published inMolecular pharmaceutics Vol. 18; no. 11; pp. 4131 - 4139
Main Authors Austerberry, James, Edwards, John, Eyes, Tim, Derrick, Jeremy P
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 01.11.2021
Subjects
Online AccessGet full text
ISSN1543-8384
1543-8392
1543-8392
DOI10.1021/acs.molpharmaceut.1c00543

Cover

Loading…
Abstract Methods to optimize the solution behavior of therapeutic proteins are frequently time-consuming, provide limited information, and often use milligram quantities of material. Here, we present a simple, versatile method that provides valuable information to guide the identification and comparison of formulation conditions for, in principle, any biopharmaceutical drug. The subject protein is incubated with a designed synthetic peptide microarray; the extent of binding to each peptide is dependent on the solution conditions. The array is washed, and the adhesion of the subject protein is detected using a secondary antibody. We exemplify the method using a well-characterized human single-chain Fv and a selection of human monoclonal antibodies. Correlations of peptide adhesion profiles can be used to establish quantitative relationships between different solution conditions, allowing subgrouping into dendrograms. Multidimensional reduction methods, such as t-distributed stochastic neighbor embedding, can be applied to compare how different monoclonals vary in their adhesion properties under different solution conditions. Finally, we screened peptide binding profiles using a selection of monoclonal antibodies for which a range of biophysical measurements were available under specified buffer conditions. We used a neural network method to train the data against aggregation temperature, k D, percentage recovery after incubation at 25 °C, and melting temperature. The results demonstrate that peptide binding profiles can indeed be effectively trained on these indicators of protein stability and self-association in solution. The method opens up multiple possibilities for the application of machine learning methods in therapeutic protein formulation.
AbstractList Methods to optimize the solution behavior of therapeutic proteins are frequently time-consuming, provide limited information, and often use milligram quantities of material. Here, we present a simple, versatile method that provides valuable information to guide the identification and comparison of formulation conditions for, in principle, any biopharmaceutical drug. The subject protein is incubated with a designed synthetic peptide microarray; the extent of binding to each peptide is dependent on the solution conditions. The array is washed, and the adhesion of the subject protein is detected using a secondary antibody. We exemplify the method using a well-characterized human single-chain Fv and a selection of human monoclonal antibodies. Correlations of peptide adhesion profiles can be used to establish quantitative relationships between different solution conditions, allowing subgrouping into dendrograms. Multidimensional reduction methods, such as t-distributed stochastic neighbor embedding, can be applied to compare how different monoclonals vary in their adhesion properties under different solution conditions. Finally, we screened peptide binding profiles using a selection of monoclonal antibodies for which a range of biophysical measurements were available under specified buffer conditions. We used a neural network method to train the data against aggregation temperature, kD, percentage recovery after incubation at 25 °C, and melting temperature. The results demonstrate that peptide binding profiles can indeed be effectively trained on these indicators of protein stability and self-association in solution. The method opens up multiple possibilities for the application of machine learning methods in therapeutic protein formulation.Methods to optimize the solution behavior of therapeutic proteins are frequently time-consuming, provide limited information, and often use milligram quantities of material. Here, we present a simple, versatile method that provides valuable information to guide the identification and comparison of formulation conditions for, in principle, any biopharmaceutical drug. The subject protein is incubated with a designed synthetic peptide microarray; the extent of binding to each peptide is dependent on the solution conditions. The array is washed, and the adhesion of the subject protein is detected using a secondary antibody. We exemplify the method using a well-characterized human single-chain Fv and a selection of human monoclonal antibodies. Correlations of peptide adhesion profiles can be used to establish quantitative relationships between different solution conditions, allowing subgrouping into dendrograms. Multidimensional reduction methods, such as t-distributed stochastic neighbor embedding, can be applied to compare how different monoclonals vary in their adhesion properties under different solution conditions. Finally, we screened peptide binding profiles using a selection of monoclonal antibodies for which a range of biophysical measurements were available under specified buffer conditions. We used a neural network method to train the data against aggregation temperature, kD, percentage recovery after incubation at 25 °C, and melting temperature. The results demonstrate that peptide binding profiles can indeed be effectively trained on these indicators of protein stability and self-association in solution. The method opens up multiple possibilities for the application of machine learning methods in therapeutic protein formulation.
Methods to optimize the solution behavior of therapeutic proteins are frequently time-consuming, provide limited information, and often use milligram quantities of material. Here, we present a simple, versatile method that provides valuable information to guide the identification and comparison of formulation conditions for, in principle, any biopharmaceutical drug. The subject protein is incubated with a designed synthetic peptide microarray; the extent of binding to each peptide is dependent on the solution conditions. The array is washed, and the adhesion of the subject protein is detected using a secondary antibody. We exemplify the method using a well-characterized human single-chain Fv and a selection of human monoclonal antibodies. Correlations of peptide adhesion profiles can be used to establish quantitative relationships between different solution conditions, allowing subgrouping into dendrograms. Multidimensional reduction methods, such as t-distributed stochastic neighbor embedding, can be applied to compare how different monoclonals vary in their adhesion properties under different solution conditions. Finally, we screened peptide binding profiles using a selection of monoclonal antibodies for which a range of biophysical measurements were available under specified buffer conditions. We used a neural network method to train the data against aggregation temperature, k D, percentage recovery after incubation at 25 °C, and melting temperature. The results demonstrate that peptide binding profiles can indeed be effectively trained on these indicators of protein stability and self-association in solution. The method opens up multiple possibilities for the application of machine learning methods in therapeutic protein formulation.
Methods to optimize the solution behavior of therapeutic proteins are frequently time-consuming, provide limited information, and often use milligram quantities of material. Here, we present a simple, versatile method that provides valuable information to guide the identification and comparison of formulation conditions for, in principle, any biopharmaceutical drug. The subject protein is incubated with a designed synthetic peptide microarray; the extent of binding to each peptide is dependent on the solution conditions. The array is washed, and the adhesion of the subject protein is detected using a secondary antibody. We exemplify the method using a well-characterized human single-chain Fv and a selection of human monoclonal antibodies. Correlations of peptide adhesion profiles can be used to establish quantitative relationships between different solution conditions, allowing subgrouping into dendrograms. Multidimensional reduction methods, such as t-distributed stochastic neighbor embedding, can be applied to compare how different monoclonals vary in their adhesion properties under different solution conditions. Finally, we screened peptide binding profiles using a selection of monoclonal antibodies for which a range of biophysical measurements were available under specified buffer conditions. We used a neural network method to train the data against aggregation temperature, , percentage recovery after incubation at 25 °C, and melting temperature. The results demonstrate that peptide binding profiles can indeed be effectively trained on these indicators of protein stability and self-association in solution. The method opens up multiple possibilities for the application of machine learning methods in therapeutic protein formulation.
Author Edwards, John
Austerberry, James
Eyes, Tim
Derrick, Jeremy P
AuthorAffiliation School of Biological Sciences, Faculty of Biology, Medicine, and Health
AuthorAffiliation_xml – name: School of Biological Sciences, Faculty of Biology, Medicine, and Health
Author_xml – sequence: 1
  givenname: James
  surname: Austerberry
  fullname: Austerberry, James
– sequence: 2
  givenname: John
  surname: Edwards
  fullname: Edwards, John
– sequence: 3
  givenname: Tim
  surname: Eyes
  fullname: Eyes, Tim
– sequence: 4
  givenname: Jeremy P
  orcidid: 0000-0002-4350-5354
  surname: Derrick
  fullname: Derrick, Jeremy P
  email: Jeremy.Derrick@manchester.ac.uk
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34658237$$D View this record in MEDLINE/PubMed
BookMark eNqNkctOwzAQRS1URB_wC8js2LT4kcTOsqooVCqii7KOHNuhrhI72AlS_x5XLZXYsboz8rmj8dwxGFhnNQAPGM0wIvhJyDBrXN3uhG-E1H03wxKhNKFXYISjTDnNyeBS82QIxiHsESJJSugNGNIkSzmhbATqj6Chq-BGt51RGr4Z6Z3wXhwCrJyHSxE6KKyCKxvbRnTmW8ONd5Wpjf08Orc77UUblzASzm1nSqcOcBnZvo60s3DhrDLHKtyC60rUQd-ddQK2y-ft4nW6fn9ZLebrqaCIdVNVMcKQzJTEWHOkMsIIT0qJBeUZp2mmMsHjO5NZVZUsL_M8EanKE5xqxhidgMfT2Na7r16HrmhMkLquhdWuDwVJOaUE8ygTcH9G-7LRqmi9aYQ_FL8HikB-AuJZQvC6uiAYFccwihhG8SeM4hxG9KYn7xHZu97b-Ol_-H4AW1uV-A
Cites_doi 10.1038/s41573-019-0028-1
10.1021/acs.biochem.9b00367
10.1016/j.jpba.2020.113703
10.1002/bit.22702
10.1073/pnas.1616408114
10.1016/j.ejpb.2017.01.019
10.1093/toxsci/kfw121
10.1021/acs.molpharmaceut.9b00852
10.1371/journal.pone.0168453
10.1073/pnas.1810576116
10.1093/bioinformatics/btl117
10.1038/nbt1000
10.1016/j.molimm.2018.11.020
10.1007/s11095-008-9737-6
10.3389/fimmu.2016.00394
10.1080/19420862.2020.1743053
ContentType Journal Article
Copyright 2021 American Chemical Society
Copyright_xml – notice: 2021 American Chemical Society
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1021/acs.molpharmaceut.1c00543
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1543-8392
EndPage 4139
ExternalDocumentID 34658237
10_1021_acs_molpharmaceut_1c00543
c453877971
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Biotechnology and Biological Sciences Research Council
  grantid: BB/L006391/1
– fundername: Biotechnology and Biological Sciences Research Council
  grantid: BB/M006913/1
GroupedDBID -
123
4.4
53G
55A
5VS
7~N
AABXI
ABFRP
ABMVS
ABUCX
ACGFS
ACS
AEESW
AENEX
AFEFF
AHGAQ
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
CS3
DU5
EBS
ED
F5P
GGK
GNL
H~9
IH9
JG
P2P
RNS
ROL
UI2
VF5
VG9
W1F
X
---
-~X
AAYXX
ABBLG
ABJNI
ABLBI
ABQRX
ADHLV
BAANH
CITATION
CUPRZ
ED~
JG~
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-a307t-df7270c6dc11e80d627284bc1a3868356d6a80c67c6ffb79b994a5d9415e7773
IEDL.DBID ACS
ISSN 1543-8384
1543-8392
IngestDate Fri Jul 11 01:27:05 EDT 2025
Thu Jan 02 22:55:12 EST 2025
Tue Jul 01 04:33:51 EDT 2025
Wed Nov 03 07:36:19 EDT 2021
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords formulation
peptide
microarray
biopharmaceutical
monoclonal antibody
Language English
License https://doi.org/10.15223/policy-029
https://doi.org/10.15223/policy-037
https://doi.org/10.15223/policy-045
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a307t-df7270c6dc11e80d627284bc1a3868356d6a80c67c6ffb79b994a5d9415e7773
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-4350-5354
PMID 34658237
PQID 2583321858
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_2583321858
pubmed_primary_34658237
crossref_primary_10_1021_acs_molpharmaceut_1c00543
acs_journals_10_1021_acs_molpharmaceut_1c00543
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20211101
2021-11-01
PublicationDateYYYYMMDD 2021-11-01
PublicationDate_xml – month: 11
  year: 2021
  text: 20211101
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Molecular pharmaceutics
PublicationTitleAlternate Mol. Pharmaceutics
PublicationYear 2021
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References ref9/cit9
ref6/cit6
ref10/cit10
ref3/cit3
ref11/cit11
ref12/cit12
ref15/cit15
ref16/cit16
ref13/cit13
ref14/cit14
ref8/cit8
ref5/cit5
ref2/cit2
ref4/cit4
ref1/cit1
van der Maaten L. (ref17/cit17) 2008; 9
ref7/cit7
References_xml – ident: ref1/cit1
  doi: 10.1038/s41573-019-0028-1
– ident: ref11/cit11
  doi: 10.1021/acs.biochem.9b00367
– ident: ref7/cit7
  doi: 10.1016/j.jpba.2020.113703
– volume: 9
  start-page: 2579
  year: 2008
  ident: ref17/cit17
  publication-title: J. Mach. Learn. Res.
– ident: ref13/cit13
  doi: 10.1002/bit.22702
– ident: ref3/cit3
  doi: 10.1073/pnas.1616408114
– ident: ref14/cit14
  doi: 10.1016/j.ejpb.2017.01.019
– ident: ref16/cit16
  doi: 10.1093/toxsci/kfw121
– ident: ref6/cit6
  doi: 10.1021/acs.molpharmaceut.9b00852
– ident: ref9/cit9
  doi: 10.1371/journal.pone.0168453
– ident: ref5/cit5
  doi: 10.1073/pnas.1810576116
– ident: ref12/cit12
  doi: 10.1093/bioinformatics/btl117
– ident: ref10/cit10
  doi: 10.1038/nbt1000
– ident: ref15/cit15
  doi: 10.1016/j.molimm.2018.11.020
– ident: ref8/cit8
  doi: 10.1007/s11095-008-9737-6
– ident: ref2/cit2
  doi: 10.3389/fimmu.2016.00394
– ident: ref4/cit4
  doi: 10.1080/19420862.2020.1743053
SSID ssj0024523
Score 2.3314774
Snippet Methods to optimize the solution behavior of therapeutic proteins are frequently time-consuming, provide limited information, and often use milligram...
SourceID proquest
pubmed
crossref
acs
SourceType Aggregation Database
Index Database
Publisher
StartPage 4131
SubjectTerms Antibodies, Monoclonal - chemistry
Antibodies, Monoclonal - therapeutic use
Biological Products - chemistry
Biological Products - therapeutic use
Chemistry, Pharmaceutical - methods
Humans
Machine Learning
Peptides - chemistry
Protein Array Analysis - methods
Protein Stability
Single-Chain Antibodies - chemistry
Single-Chain Antibodies - therapeutic use
Title Use of Peptide Microarrays for Fast and Informative Profiling of Therapeutic Antibody Formulation Conditions
URI http://dx.doi.org/10.1021/acs.molpharmaceut.1c00543
https://www.ncbi.nlm.nih.gov/pubmed/34658237
https://www.proquest.com/docview/2583321858
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlZ1bS8MwFIAPOkF88X6ZNyLInuxsmy5pH2U4hqAMnLC3kiYpiNrK0j3MX-9J2zmniPraJqFNz8n56LkBnAvtKo0k7WjkZSdQkXIiVypHBcJNXKpTtwqQvWP9h-Bm1BnN87i_evB971JI037JbeJp_Yu37UkLGnQZVnyGymx5qHs_L7DXKXu6IRpQJ6RhsApnvy5lTZM0i6bpB94s7U5vA4az7J0q3OSpPSmStnz7XszxP6-0Ces1h5KrSnC2YEln29AaVGOnF2Q4z8syF6RFBvMS19MdeH4wmuQpGdiYGKXJrQ3rE-OxmBqCFEx6whREZIrU2U72TCWDsj04mko789P65CorHpNcTUkPx9btxEg3t850qxS7MOxdD7t9p-7b4Ag8MQpHpQhFrmRKep4OXcV8jkYwkZ6gIUPiY4qJEO9zydI04VESRYHoqAhZQnPO6R40sjzTB0A0LeNQdUBDHbBUJlwpISLJtMeRW2gTUOpMXKudiUuPuu_F9uLCBsf1BjfBn33i-LUq5_GXSWczYYhR-axHRWQ6n5jYtzlrCEmdsAn7lZR8LEsDhDuf8sP_PuMRrPk2cKZMeDyGRjGe6BMknyI5LSX9HV0JBA0
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3Na9swFMAfawftLvtqu2WfKoye6tS2HMk-hrCQbW0JNIVCD0aWZBjb7BE5h-yv33uymyyFsnVXWRKy_KT3w-8L4IOyobFI0oFFXg4Sk5kgC7UJTKLCIuS2DFsH2XMxuUw-Xw2uOq9KioXBRTicyXkj_jq7QHRCbT9qij_t_vT2I028wbfgIUJJTNI9HF2s8-wNfGk3JAQepDxNduDwr1ORhtJuU0PdgZ1e_YyfwPVq4d7r5Ft_0RR9_etWTsf_e7On8LijUjZsxegZPLDVcziatn2Xx2y2jtJyx-yITdcJr5d78P3SWVaXbEoeMsayM3LyU_O5WjqGTMzGyjVMVYZ1sU90w7KpLxaOipNG_jE_G1bN16I2SzbGvl1xMTaqybROR2QfZuOPs9Ek6Ko4BArvjyYwJSJSqIXRUWTT0IhYokosdKR4KpD_hBEqxedSi7IsZFZkWaIGJkOysFJKfgDbVV3Zl8As916pNuGpTUSpC2mMUpkWNpJIMbwHtL95dwhd7u3rcZRT48YG590G9yC--dL5zza5x78MOryRiRyPItlXVGXrhctjimBDZBqkPXjRCstqWp4g6sVcvrrvGt_D7mR2dpqffjr_8hoexeRS40Mh38B2M1_Yt8hETfHOC_9vckYMbg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7aFEIvfbfZPhUoOcUb2_Ja9nHZ1qSvYOgGchOyJENpY4eV97D99Z2RlWxTKH1cZWmQRzOaD80L4LWysbGIpCOLeDnKTGmiMtYmMpmKm5jbNh4DZE_y49Ps_dnsLDy4US4MbsIhJeed-KTVF6YNFQaSIxo_7ykHNbz2ThNNmIPfhFvkviMJny8-b2vtzXx7N0QJPCp4ke3C_h9JkZXS7rqV-g309CaougvyavM-8uTrdD00U_39l7qO__939-BOQKdsPorTfbhhuwdwUI9zN4dsuc3WcofsgNXbwtebh_Dt1FnWt6ymSBlj2ScK9lOrldo4htiYVcoNTHWGhRwoumlZ7ZuGowGllT_RZ_Nu-NL0ZsMqnBuajLFFTy52UpVHsKzeLhfHUejmECm8R4bItAiVYp0bnSS2iE2eCjSNjU4UL3LEgbnJVYHfhc7bthFlU5aZmpkSEYYVQvDHsNP1nd0DZrmPTrUZL2yWt7oRxihV6twmAtEMnwDxWAZldNL72dNE0uA1BsvA4Amkl6ctL8YiH3-zaP9SLiSqJPlZVGf7tZMpZbIhdJoVE3gyCswVWZ4h5Eu5ePqve3wFu_WbSn58d_LhGdxOKbLGZ0Q-h51htbYvEBoNzUsv_z8A8lEO8Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Use+of+Peptide+Microarrays+for+Fast+and+Informative+Profiling+of+Therapeutic+Antibody+Formulation+Conditions&rft.jtitle=Molecular+pharmaceutics&rft.au=Austerberry%2C+James&rft.au=Edwards%2C+John&rft.au=Eyes%2C+Tim&rft.au=Derrick%2C+Jeremy+P&rft.date=2021-11-01&rft.issn=1543-8392&rft.eissn=1543-8392&rft.volume=18&rft.issue=11&rft.spage=4131&rft_id=info:doi/10.1021%2Facs.molpharmaceut.1c00543&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1543-8384&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1543-8384&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1543-8384&client=summon